Caveolins are scaffolding proteins that play a pivotal role in numerous processes, including caveolae biogenesis, vesicular transport, cholesterol homeostasis and regulation of signal transduction. There are three different isoforms 
Introduction
Caveolins are membrane scaffolding proteins that regulate numerous processes in a variety of tissues and cell types [1, 2] . They participate in the biogenesis of caveolae, flaskshaped invaginations of the plasma membrane where several molecules involved in the regulation of transduction pathways are specifically and highly enriched [3] [4] [5] . Caveolins are anchored at the inner leaflet of caveolae through a short hairpin hydrophobic domain and protrude towards the cytoplasm, where they can bind and influence the activity of several protein partners via a caveolin scaffolding domain (CSD) [6, 7] . In skeletal muscle, in particular, Cav-1 expression is restricted to satellite cells [8] [9] [10] , whereas Cav-3 plays a pivotal role in the mature myofibres [11] [12] [13] , as demonstrated by the fact that its deficiency is associated to a set of genetic muscular disorders, known as caveolinopathies [14] [15] [16] [17] . Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma occurring in childhood and sharing features of myogenic cells [18] [19] [20] . Hence, cancerous RMS cells can be univocally identified by means of muscle markers [21] . Two different [22, 23] . This review will summarize these findings and highlight the relevance of caveolins as diagnostic markers for the detection of RMS with a different grading. In addition, the potential contribution of caveolins to the progression of RMS is discussed, particularly for Cav-1.
Caveolae and caveolins
Caveolae are characteristic flask-shaped invaginations of the plasma membrane that configure as specialized microdomains involved in numerous functions, including cell signalling, lipid regulation and endocytosis [1] [2] [3] [4] [5] [6] [7] . Cav-1, Cav-2 and Cav-3 are the main structural proteins of caveolae and are codified by three different genes that have a high degree of homology [1, 2] (Table 1 ). In particular, caveolins are anchored to the inner leaflet of the plasma membrane via a short hydrophobic loop, which allow them to assume a unique hairpin structure, characterized by the presence of both N-and Cterminal portions facing towards the cytoplasm [1, 2] . Cav-1 and Cav-2 form hetero-oligomers and are ubiquitously co-expressed [24] , whereas Cav-3 forms homo-oligomers that are predominantly expressed in skeletal and cardiac muscle [11, 12] (Table 1) . Cav-1 and Cav-3 are unequivocally required for the biogenesis of caveolae [25] , as corroborated by the lack of caveolae in Cav-1 null animals [26] and in muscle and cardiac tissues of Cav-3 null animals [27, 28] , despite other key protein molecules, such as PTRF-Cavin [29, 30] and ARAF-1 [31] , seem to have a role in the formation of these membranous structures. Although caveolins are predominantly recovered at the plasma membrane and in Golgi apparatus of cells [32] [33] [34] , their subcellular localization may change upon posttranslational modifications, as occurs for Cav-1, which may be targeted to cytoplasm or secretory vesicles upon phosphorylation on Tyr14 or Ser80 residues, respectively [35, 36] .
Caveolins as scaffolding proteins
The most important feature of caveolins relies on their ability to bind and modulate the biological activity of a multitude of intracellular protein partners through the so-called CSD, which recognises motifs enriched of aromatic residues [6, 37] 
Role of caveolins in skeletal muscle
In skeletal muscle, Cav-1 and Cav-3 reside in satellite cells [8] [9] [10] and myofibres [11] [12] [13] 
Alveolar RMS

ARMS mainly affect adolescents and adults and are characterized by a poorer prognosis. ARMS cells resemble lung alveoli, with clusters of eosinophilic tumour cells arranged loosely and disposed in an alveolar pattern. ARMS typically occur in the trunk and body extremities [108] and frequently harbour non-random chromosomal translocations [125] (Fig. 1). In particular, translocations t(2;13)(q35;q14) and t(1;13)(p36;q14) account respectively for about 70% and 10% of ARMS and give rise to chimeric proteins that are formed by the fusion of the paired and homeo-DNA binding domain of PAX3 or PAX7 factors with the transactivation domain of FKHR (FOXO1) [126-128]. The so-called PAX3-FKHR and PAX7-FKHR transcription factors enable an aberrant transcriptional program and significantly contribute to RMS progression through multiple mechanisms. In particular, PAX3-FKHR and PAX7-FKHR are frequently overexpressed in ARMS [129], display incremented accessibility to chromatin due to localization exclusively nuclear [130-132] and reach a 10-to 100-fold increase in the transcriptional activation of downstream target genes in com-
Principal pathways and targets deregulated in RMS
The network of pathways deregulated in RMS is rather complex (Fig. 1) 153] , VEGF [154] [155] [156] , FGFR4 [157] and IL-4R [158, 159] . The overactivation of the RAS pathway occurs rather frequently [122] [123] [124] . In addition to the peculiar PAX3/7-FKHR expression [126] [127] [128] [161] , N-and C-MYC [162] [163] [164] , MDM2 [144, 165] and some mutations in the cyclin-dependent kinases (CDKs) genes [166] [167] , such as the inactivation of the mitogen-activated protein kinase (MAPK) p38 [168] , whose function is required to enable MyoD transcriptional activity [169] , or the presence of E-proteins complexes that compete for the generation of active full-length E-protein/MyoD heterodimers [170] . Moreover, PAX3-FKHR factor has been shown to increment the transcriptional levels of MyoD, but then abrogates its activity through protein phosphorylation [171, 172] . (Fig. 1) . In particular, RMS development occurs in p53-mutant mice [173, 174] and tumour incidence increases in conjunction with loss of FOS [175] , activation of HER-2/neu [176] , RAS [177] or the expression of PAX3/7-FKHR proteins [178] . In addition, mice with ablated PTCH gene [179] or with aberrant HGF signalling [146, 147] and nontransgenic dystrophin-deficient mdx mice [180] [182] , Costello syndrome [183] , Gorlin syndrome [184] , retinoblastoma [185] , mosaic variegated aneuploidy syndrome [186] and mismatch repair deficiency syndrome [187] (Fig. 1) . [188] [189] [190] . In particular, inactivation of p53 cooperates with oncogenic RAS in muscle precursors and satellite cells to induce ERMS in mice [191] and zebrafish models [181] . On [192, 193] . These findings strongly support the notion that PAX3/7-FKHR factors may confer the myogenic identity to MSCs elements [188] , but then secondary deregulated mechanisms are required to induce tumour formation. [194, 195] . The analysis of Cav-1 behaviour was then particularly characterized by employing RD cells, an RMS model line in which RAS mutations are long known to counteract the myogenic differentiation via hyperactivation of the ERK pathway [196] . In RD cells, Cav-1 was found to be properly localized at the plasma membrane (Fig. 3B) [177, 181, 183, [190] [191] [192] [193] [197, 198] . Thus, the presumed impaired ability of Cav-1 to control cell proliferation in RMS cells needs to be ascertained also in relation to Cav-2 functionality.
Animal models and human syndromes associated to RMS
A growing body of evidence derived from different animal models suggests that the development of RMS frequently occurs upon suppression of p53 pathway in conjunction with deregulated activities of receptorial systems along the RAS axis and/or the expression of PAX3/7-FKHR gene products
Origins of RMS
Despite great efforts have been made to understand the molecular signatures of RMS, the identity of the tumour-initiating cell remains to be clarified. Satellite cells and multipotent mesenchymal stem cells (MSCs) are thought to be the most credited source for ERMS and ARMS, respectively
Expression of caveolins in RMS tumours and cell lines
Future perspectives: assessing the role of caveolins in RMS tumour progression
At the plasma membrane caveolins control the activity of several proteins involved in pathways transduction, thereby representing a checkpoint of cellular signalling. As such, in the following paragraphs the potential relationship between caveolins and different pathways which are central to RMS development will be discussed (Table 2).
Cav-1 and p53 signalling
Inactivation of p53 pathway, as occurs for spontaneous p53 germline mutations [141] or overexpression of MDM2 [144, 165], plays a critical role for RMS development. As effect of p53 loss of function, cancerous cells elude senescence and divide indefinitely. In this context, cellular senescence may represent a tumour-suppressor mechanism.
In fibroblasts subjected to oxidative stress, Cav-1 has emerged as promoter of cell senescence [199] [200] [201] in virtue of its ability to sequester MDM2 [202] , a negative regulator of p53 activity, or inhibit the activity of anti-oxidant enzymes, such as thioredoxin reductase 1 [203] . These findings suggest an investigation on the potential role of Cav-1 in controlling the p53 pathway in RMS cells. [150, 153] and VEGFR [154] [155] [156] . [204] [205] [206] [207] , although it is a negative regulator of EGFR [208] , PDGFR [209] and VEGFR-2 activities [210] . Therefore, the ability of these receptorial systems to generate downstream signalling may be influenced, at least in part, by deregulated expression and/or localization of Cav-1, leading to a significant change in the biological outcome promoted by each pathway. [212] . Thus, it is important to establish how the association between high Cav-1 expression and elevated RAS/ERK pathway might influence RMS cell behaviour.
Cav-1 and multiple control of receptorial systems for growth factors
Different receptorial systems for growth factors have been shown to signal aberrantly in RMS cells, including those for IGF-1R [148-150], EGFR [151, 152], PDGFR
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Fig. 3 Expression of caveolins in RMS cell lines. (A) Western blot analyses showing the expression of Cav-1 in several MyoD-positive ERMS cell lines. Tubulin was used as loading control. (B) As shown by confocal microscopy analysis, Cav-1 localizes at the plasma membrane or in intracellular vesicles of embryonal RD cells. GM130 marker was employed to stain the Golgi apparatus. Bars ϭ 100 m. (C) Ten microliters of PD98059 administration attenuates the ERK phosphorylation in RD cells and allows the transition from proliferation to differentiation, leading to Cav-1 down-regulation and increase of myogenin, MHC and Cav-3. Tubulin was used as loading control.
Remarkably, Cav-1 exerts a multiple physiological control on several components of these pathways through multiple mechanisms, such as physical interaction, regulation of receptor phosphorylation and internalization. In particular, Cav-1 configures as a positive regulator of IGF-1R pathways
Cav-1 and RAS/ERK signalling
Overactivation of RAS/ERK signalling is one of the factors predisposing to RMS [122-124, 177, 181, 106]. Historically, Cav-1 configures as a strong inhibitor of this pathway in several cell types and tissues [10, 53, 59, 211]. Actually, the elevated Cav-1 expression detected in human RMS embryonal RD cells has been correlated to hyperactivation of the ERK pathway (Fig. 3C) [23]. These findings indicate that, at least in RD cells, Cav-1 seems to be aberrantly converted to a downstream target of the ERK pathway, giving rise to an ambiguous situation, in which cell proliferation is associated to persistent Cav-1 expression, suggesting that Cav-1 has lost the ability to antagonize the RAS/ERK signalling. The main hypotheses explaining this behaviour could be referred to an impaired activity of additional proteins which might cooperate with Cav-1 in the inhibition of the RAS/ERK pathway; alternatively, the antagonistic role of Cav-1 on the ERK pathway might occur upstream RAS, thus rendering ineffective its inhibition in the presence of activating RAS mutations. In this regard, it is known that hyperactivation of the ERK pathway cooperates to shift the function of some proteins, as occurs for Sprouty-1, which changes its function from antagonist to agonist of the RAS/ERK pathway in ERMS tumours harbouring activating RAS mutations
Caveolins and TGF-␤/myostatin signalling
Caveolins are long known to limit the TGF-␤ pathway [213] , which is supposed to play a not less important role in RMS [214] [215] [216] [217] [218] . [208] . [151, 152] . [209] .
HER1/EGFR is mainly expressed in ERMS, HER-2/EGFR in ARMS
PDGFR
Cav-1 inhibits the autophosphorylation of PDGF receptors in a dose-dependent manner
Both ERMS and ARMS overexpress PDGFR-A and its ligands PDGF-C and PDGF-A [150, 153].
VEGFR Cav-1 acts as a negative regulator of VEGFR-2 activity in endothelial caveolae [210] . Autocrine VEGF secretion stimulates RMS cell growth [154] [155] [156] . [53, 59, 211] , including muscle satellite cells [10] . [122] [123] [124] 196] and favour ERMS tumours [177, 181, 183, [190] [191] [192] [193] . [213] . [214] [215] [216] [217] [218] .
RAS/ERK Cav-1 limits the RAS/ERK pathway activation in several cell types
Activating RAS mutations are detected in ERMS cell lines
TGF-␤/ myostatin
Cav-1 interacts with TGF-␤ type I receptors (ALK receptors) to limit the activation of TGF-␤ pathways
TGF-␤ superfamily members, such as TGF-␤ and myostatin, may impair RMS differentiation
HGF/cMET Cav-1 is a downstream target of the HGF/cMET signalling axis in muscle satellite cells [10].
Transgenic mice overexpressing HGF develop cancer, including RMS [146, 147].
cMET is frequently overexpressed in RMS [160] . [227] and endothelial smooth muscle cells [228] . [229, 230] . 2561 [219] [220] [221] and proceed from the cell membrane to the nucleus through the cooperation of the types I and II serine/threonine kinase receptors (T␤R-I and -II) and their downstream SMAD effectors [222] . Different TGF-␤ ligands, such as TGF-␤ [214] and myostatin [223] , have been implicated in poor differentiation of RD cells [214] [215] [216] [217] [218] [227] and endothelial smooth muscle cells [228] 
RAGE
Cav-1 is a downstream target of RAGE-mediated Src activation in Schwann cells
Low RAGE expression in myoblasts and RMS cells correlates with increased proliferation, migration, invasiveness and tumour growth
Transforming growth factor-␤ (TGF-␤) signalling pathways regulate numerous physiological and pathological processes
Caveolins and RAGE signalling
Receptor for advanced glycation end-products (RAGE) is a multiligand receptor of the immunoglobulin superfamily with a positive or negative role in cancer progression and metastasis depending on the tumour type [226]. A role of RAGE in regulating Cav-1 and Cav-3 expression/phosphorylation has been reported in several cell types. Indeed, (i) RAGE-mediated Src activation induces Cav-1 phosphorylation in Schwann cells
